Phase II Trial of Tislelizumab, an Anti-PD-1 Monoclonal Antibody, in Combination With Dasatinib and Quercetin, as a Novel Neoadjuvant Pre-Surgical Therapy for Head and Neck Squamous Cell Carcinoma.
We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.